跳至主要内容
临床试验/NCT00840242
NCT00840242已完成3 期

Smoking Reduction or Cessation With Nicotine Replacement Therapy. A Placebo Controlled Double Blind Trial With Nicotine Gum or Inhaler.

McNeil AB2 个研究点 分布在 1 个国家目标入组 314 人开始时间: 1999年2月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
McNeil AB
入组人数
314
试验地点
2
主要终点
Reduction in number of smoked cigarettes/day verified by carbon monoxide (CO) levels

研究概览

简要总结

The purpose of this study is to test the success rate of smoking reduction or cessation with different nicotine products.

详细描述

To test if smoking reduction or cessation is induced with different nicotine products and to investigate the possible health benefits of smoking reduction

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age above 18
  • Smoking >/= 15 cigarettes/day
  • Having smoked for 3 years or more
  • CO >/= 10ppm at inclusion
  • Want to reduce smoking
  • Prepared to adhere to the protocol
  • Willing to provide signed informed consent
  • Having made at least one serious attempt to quit smoking

排除标准

  • Unstable angina pectoris, myocardial infarction within the last three months
  • Use of other nicotine-containing products such as cigars, pipes, snuff
  • Current use of NRT or involved in behavioral or pharmacological smoking cessation/reduction program
  • Pregnancy/lactation or intended pregnancy
  • Under psychiatric care or medication that might interfere with the trial
  • Abuse of alcohol or any other drug

研究组 & 干预措施

Nicotine gum

Experimental

Nicotine gum

干预措施: Nicotine gum (Drug)

Placebo gum

Placebo Comparator

Placebo gum

干预措施: Placebo gum (Drug)

Nicotine inhaler

Active Comparator

Nicotine inhaler

干预措施: Nicotine inhaler (Drug)

Placebo inhaler

Placebo Comparator

Placebo inhaler

干预措施: Placebo inhaler (Drug)

结局指标

主要结局

Reduction in number of smoked cigarettes/day verified by carbon monoxide (CO) levels

时间窗: Baseline to 6 weeks, 3 and 4 months

次要结局

  • Changes in laboratory values of cardiovascular risk factors(Baseline up to 12 months)
  • Changes in clinical and laboratory exposure parameters(Baseline up to 12 months)

研究者

发起方
McNeil AB
申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验